抗疱疹药物无环鸟苷(acyclcovir:ACV)的开发,不仅作为临床治疗用药有其实用价值,还证明了在开发对病毒高选择毒性药物具有更大的价值。随着AIDS的出现,关于抗病毒药的研究显著增加,在如此激烈的竞争中,在实验室水平上又找到了不少超出ACV的抗疱疹活性的药物。在日本,已从一种酱油中开发出BV ara U(bromovinylara uridine,溴乙烯阿糖尿苷), 据报告对带状疱疹病毒(VZV)化学治疗系 The development of the anti-herpes drug acyclcovir (ACV) not only has practical value as a clinical therapeutic drug but also has proved to be of even greater value in the development of highly selective toxic drugs against viruses. With the advent of AIDS, there has been a significant increase in research on antiviral drugs, and in such fierce competition a number of drugs have been found on laboratory level that exceed the anti-herpetic activity of ACV. In Japan, BV ara U (bromovinylararidine) has been developed from a soy sauce, and the treatment of herpes zoster virus (VZV)